Scholar Rock Holding Corp's Chief Financial Officer Vikas Sinha reported an open-market sale of 10,410 shares of common stock at an average price of $49.5745 per share on April 16, 2026. According to the footnotes, this sale was required solely to cover tax withholding obligations tied to restricted stock units that vested on April 15, 2026, under the company’s equity incentive plans and was not a discretionary trade.
After this transaction, Sinha’s reported equity position totals 619,856 equity-linked interests, consisting of 47,835 shares of common stock, 122,021 time-based RSUs, and 450,000 RSUs subject to performance- and time-based vesting conditions. The RSU awards referenced in the transaction were granted on April 27, 2025 and vest annually over four years, contingent on continued service.
Scholar Rock Holding Corp's CEO David Hallal reported a tax-driven share sale tied to equity compensation. On April 15, 2026, restricted stock units vested, and 30,615 shares of common stock were sold at an average price of $49.5745 per share to cover related tax withholding obligations. The filing states this mandatory "sell to cover" transaction was executed through a designated brokerage firm and was not a discretionary trade by Hallal. After the sale, he directly held 1,639,034 shares of common stock. He also has additional exposure through 198,530 shares of common stock, 315,504 time-based RSUs, and 1,125,000 performance- and time-based RSUs, plus indirect holdings in the Hallal Family Irrevocable Trust, for which he disclaims full beneficial ownership.
Mohammed Qatanani filed a Form 144 notice to sell 23,408 shares of Common Stock on 04/06/2026 via a stock option exercise for cash. The filing lists three prior sales in the past three months: 13,112 shares on 01/14/2026, 14,898 shares on 01/22/2026, and 8,484 shares on 02/23/2026.
Scholar Rock Holding Corporation filed a current report describing that it has resubmitted its Biologics License Application (BLA) to the FDA for apitegromab, a muscle-targeted therapy for children and adults with spinal muscular atrophy (SMA).
The company anticipates FDA acceptance of the resubmitted BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026. The resubmission also adds a second U.S. fill-finish facility alongside Catalent Indiana to support the apitegromab supply chain and planned global commercial demand. In Europe, the EMA review of the apitegromab Marketing Authorisation Application is progressing, with a decision anticipated around mid-2026.
Scholar Rock Holding Corp — an amended Schedule 13G/A shows The Vanguard Group reporting 0 shares beneficially owned of common stock following an internal realignment. The filing explains that on January 12, 2026 Vanguard disaggregated certain subsidiaries under SEC Release No. 34-39538, and the amendment is signed 03/27/2026.
Scholar Rock Holding Corporation filed an amended report to correct a scrivener’s error in its prior earnings release, updating net loss per share and weighted average shares outstanding for the quarter ended December 31, 2025.
For that quarter, the company reported a net loss of $91.0 million, or $0.76 per share, compared with a net loss of $66.5 million, or $0.61 per share, a year earlier. For full year 2025, net loss was $377.9 million, or $3.29 per share, versus $246.3 million, or $2.47 per share, in 2024. Scholar Rock highlighted progress on apitegromab for spinal muscular atrophy, noting it is ready to resubmit its BLA after FDA reinspection of Novo Nordisk’s Catalent Indiana facility, and described a new multi‑tranche financing with Blue Owl Capital, including an initial $100 million used to retire its prior Oxford Finance debt and additional tranches tied to future milestones and approvals.
Scholar Rock Holding Corporation files its annual report describing a biopharmaceutical business focused on rare neuromuscular diseases, especially spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
The company’s lead antibody, apitegromab, showed positive Phase 3 SAPPHIRE results in SMA, supporting improved motor function on top of existing SMN-targeted therapies. A biologics license application received FDA priority review but then a complete response letter tied to a third-party fill‑finish facility; the company plans to resubmit after cGMP issues at that facility are resolved. An EMA marketing application for apitegromab has been validated.
Scholar Rock reports a broad pipeline including subcutaneous apitegromab, SRK‑439 for neuromuscular diseases, SRK‑181 for solid tumors resistant to anti‑PD‑(L)1 therapy, and earlier programs such as SRK‑373 and SRK‑256. As of June 30, 2025, non‑affiliate common stock market value was about $2.6 billion, and as of February 26, 2026, 114,883,096 common shares were outstanding.
Scholar Rock Holding Corporation reported wider losses for the fourth quarter and full year 2025 while highlighting progress in its spinal muscular atrophy pipeline. Quarterly net loss was $90.965 million, compared with $66.454 million a year earlier, and full-year net loss was $377.939 million versus $246.294 million in 2024.
Operating expenses rose sharply, with 2025 research and development at $208.440 million and general and administrative at $176.205 million. Cash, cash equivalents and marketable securities totaled $367.563 million as of December 31, 2025, down from $437.278 million a year earlier.
The company emphasized advancing apitegromab for SMA, citing FDA engagement and readiness to resubmit its BLA after successful reinspection of Novo Nordisk’s Catalent Indiana facility. It also highlighted SRK-439, a preclinical myostatin inhibitor, and described 2026 as potentially “transformative” as it continues to invest heavily in its neuromuscular disease portfolio.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, sold a total of 8,484 shares of common stock in open‑market transactions on February 23, 2026. The sales were executed under a pre‑established Rule 10b5‑1 trading plan adopted on March 31, 2025.
The transactions were split into three tranches: 7,427 shares at a weighted average price of $46.9422, 857 shares at $47.8588, and 200 shares at $48.4800, with each tranche covering multiple trades within stated price ranges. Following these sales, Qatanani’s reported holdings consist of 98,445 RSUs.
Mohammed Qatanani filed a Form 144 reporting a proposed sale of 8,484 shares of Common stock related to a Restricted Stock Award dated 02/15/2026. The filing also lists prior sales of Common stock on 12/04/2025 (136,462), 01/14/2026 (13,112), and 01/22/2026 (14,898). The broker noted is J.P. Morgan Securities LLC.